MEI Pharma and Infinity to merge
MEI Pharma, Inc. a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc. a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced that the companies entered into a definitive merger agreement for an all-stock transaction forming a company combining the expertise and resources of MEI and Infinity to advance a robust pipeline of three clinical-stage oncology drug candidates.
All three clinical-stage development programs have the potential, in combination with current therapies, to overcome known resistance mechanisms and meaningfully improve patient outcomes. The combined company’s clinical-stage oncology development pipeline consists of three differentiated programs: i.Eganelisib, an oral immuno-oncology macrophage reprogramming product candidate, which is planned to be evaluated in combination with the PD-1 targeted checkpoint inhibitor pembrolizumab (Keytruda)in patients with head and neck squamous cell carcinoma ; ii. Voruciclib, an oral CDK9 inhibitor, currently being studied in combination with venetoclax (Venclexta) in patients with hematologic malignancies; and iii. ME-344, a novel tumor selective mitochondrial inhibitor targeting the OXPHOS pathway, to be evaluated in combination with bevacizumab (Avastin) in patients with relapsed colorectal cancer.Under the terms of the merger agreement, Infinity will become a wholly owned subsidiary of MEI Pharma.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
